Pfizer (PFE) Tops Q4 EPS by 6c, FY18 EPS Guidance Beats, Sees $15B Repatriation Tax Liability
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on Alphabet boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Pfizer (PFE) PT Raised to $42 at UBS
January 31, 2018 9:37 AM ESTUBS raised its price target on Pfizer (NYSE: PFE) to $42.00 (from $40.00) while maintaining a Buy rating.
... MorePfizer (PFE) PT Raised to $44 at Bernstein on 4Q Beat; 'Lower than Expected Tax Rate... Decent 2018 Guidance'
January 31, 2018 8:58 AM ESTBernstein raised its price target on Pfizer (NYSE: PFE) to $44.00 (from $43.00) while maintaining a Outperform rating, following the company's fourth quarter earnings report.
Analyst Tim Anderson notes an increased price target on the shares, as PFE reported fourth quarter earnings per share and revenue... More
Pfizer (PFE) PT Raised to $42 at Deutsche Bank Following 4Q
January 31, 2018 7:39 AM ESTDeutsche Bank raised its price target on Pfizer (NYSE: PFE) to $42.00 (from $41.00) while maintaining a Buy rating following 4Q. PFE reported 4Q EPS of $0.62, well above consensus of $0.56. Revenue came in just above estimates, while gross margin was lower and operating expenses were... More
